Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting XXXX in Perspective.

@entity1 @entity6023 @entity0 @entity19878 @entity1311 @entity3907 @entity1205
UNASSIGNED: Agents that target microtubule (MT) dynamics have been used extensively for the treatment of @entity0 ( @entity0 ). Among these agents are @entity6023 (solvent-based @entity1311 [sb- @entity1311 ], @entity1205 , and nab- @entity1311 ) and non- @entity6023 , such as eribulin and @entity19878 . Although these agents have been approved for the treatment of @entity0 , questions regarding the ideal agent, regimen (single agent vs. combination vs. sequential), and schedule still remain. This systematic review examined pivotal trials for @entity6023 , eribulin, and @entity19878 as well as first-line @entity3907 trials in @entity0 . Only randomized trials that enrolled  >=  100 @entity1 were included. Publications on combination regimens with targeted agents were excluded unless they also included a comparison between nontargeted regimens. The studies were grouped into @entity3907 versus @entity3907 , sb- @entity1311 versus non- @entity3907 , and @entity1205 versus non- @entity3907 regimens. In @entity3907 versus @entity3907 comparisons, the efficacy of sb- @entity1311 and @entity1205 appeared similar, nab- @entity1311 every 3 weeks (q3w) appeared superior to sb- @entity1311 q3w, and weekly nab- @entity1311 appeared superior to @entity1205 . In general, @entity3907 regimens demonstrated higher overall response rates (ORRs) versus non- @entity3907 regimens; however, only 2 trials demonstrated longer overall survival (OS) for @entity3907 regimens. @entity6023 will likely continue to be used in earlier lines of therapy, whereas eribulin and @entity19878 may be more appropriate for later lines of treatment. Ongoing research may identify biomarkers that could help in selecting the appropriate MT-targeted agent for a given @entity1 .
